SBNO2 is a critical mediator of STAT3-driven hematological malignancies
Blood · 13.04.2023 · 141 (15) · 1831-1845
DOI: 10.1182/blood.2022018494 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, erschienen am 13.04.2023. Verfasst von Tania Brandstoetter und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Hematologic Neoplasms, STAT3 Transcription Factor. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Gain-of-function mutations in the signal transducer and activator of transcription 3 (STAT3) gene are recurrently identified in patients with large granular lymphocytic leukemia (LGLL) and in some cases of natural killer (NK)/T-cell and adult T-cell leukemia/lymphoma. To understand the consequences and molecular mechanisms contributing to disease development and oncogenic transformation, we developed murine hematopoietic stem and progenitor cell models that express mutated STAT3Y640F. These cells show accelerated proliferation and enhanced self-renewal potential. We integrated gene expression analyses and chromatin occupancy profiling of STAT3Y640F-transformed cells with data from patients with T-LGLL. This approach uncovered a conserved set of direct transcriptional targets of STAT3Y640F. Among these, strawberry notch homolog 2 (SBNO2) represents an essential transcriptional target, which was identified by a comparative genome-wide CRISPR/Cas9-based loss-of-function screen. The STAT3-SBNO2 axis is also present in NK-cell leukemia, T-cell non-Hodgkin lymphoma, and NPM-ALK-rearranged T-cell anaplastic large cell lymphoma (T-ALCL), which are driven by STAT3-hyperactivation/mutation. In patients with NPM-ALK+ T-ALCL, high SBNO2 expression correlates with shorter relapse-free and overall survival. Our findings identify SBNO2 as a potential therapeutic intervention site for STAT3-driven hematopoietic malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, Vienna, Austria.
- Research Institute of Molecular Pathology, Vienna BioCenter, Vienna, Austria.
- Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
- Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
- Department of Computer Science, Aalto University, Espoo, Finland.
- Institute for Medical Biochemistry, University of Veterinary Medicine Vienna, Vienna, Austria.
ORCID-Profile: Tania Brandstoetter, Johannes Schmoellerl, Sebastian Kollmann, Jani Huuhtanen, Thorsten Klampfl, Florian Grebien, Satu Mustjoki, Veronika Sexl
Zitieren
APA
Brandstoetter, T., Schmoellerl, J., Grausenburger, R., Kollmann, S., Doma, E., Huuhtanen, J., Klampfl, T., Eder, T., Grebien, F., Hoermann, G., Zuber, J., Mustjoki, S., Maurer, B., & Sexl, V. (2023). SBNO2 is a critical mediator of STAT3-driven hematological malignancies. Blood, 141(15), 1831-1845. https://doi.org/10.1182/blood.2022018494
Vancouver
Brandstoetter T, Schmoellerl J, Grausenburger R, Kollmann S, Doma E, Huuhtanen J, et al. SBNO2 is a critical mediator of STAT3-driven hematological malignancies. Blood. 2023;141(15):1831-1845. doi:10.1182/blood.2022018494
BibTeX
@article{Brandstoetter2023,
author = {Brandstoetter, Tania and Schmoellerl, Johannes and Grausenburger, Reinhard and Kollmann, Sebastian and Doma, Eszter and Huuhtanen, Jani and Klampfl, Thorsten and Eder, Thomas and Grebien, Florian and Hoermann, Gregor and Zuber, Johannes and Mustjoki, Satu and Maurer, Barbara and Sexl, Veronika},
title = {SBNO2 is a critical mediator of STAT3-driven hematological malignancies},
journal = {Blood},
year = {2023},
volume = {141},
number = {15},
pages = {1831--1845},
doi = {10.1182/blood.2022018494}
}
EUVIMED